# Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

> **NCT02069080** · EARLY_PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 2 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** 64-Cu-plerixafor

## Key facts

- **NCT ID:** NCT02069080
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02-20
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2018-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069080, "Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02069080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*